Colifagina, a novel preparation of 8 lysed bacteria ameliorates experimental colitis

International Journal of Immunopathology and Pharmacology

Volumn 21, Issue 2, 2008, Pages 401-407

  Vetrano, S ^a   Correale, C ^a   Borroni, E M ^a   Pagano, N ^a   Savino, B ^a   Locati, M ^a   Malesci, A ^b   Repici, A ^a   Danese, Silvio ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Colifagina; Experimental colitis; IgA; Inflammatory bowel disease; Probiotics

Indexed keywords

BACTERIAL ANTIGEN; CHEMOKINE; COLIFAGINA; DEXTRAN SULFATE; IMMUNOGLOBULIN A; MACROPHAGE INFLAMMATORY PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 2; PROBIOTIC AGENT; RANTES;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LYSATE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG EFFICACY; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; HISTOLOGY; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; INFLAMMATION; INTESTINE FLORA; MALE; MOUSE; NONHUMAN; ORGAN CULTURE; PATHOGENESIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 47249083373     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200802100219     Document Type: Article

References (20)

1. Mahida YR, Rolfe VE. Host-bacterial interactions in inflammatory bowel disease. Clin Sci (Lond) 2004; 4:331-7.
2. Baharav E, Mor F, Halpern M, Weinberger A. Lactobacillus GG bacteria ameliorate arthritis in Lewis rats. J Nutr 2004; 8:1964-9.
3. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 2:305-8.
4. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 9179:635-40.
5. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C, Sartor RB. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005; 7:1539-44.
6. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomized controlled trial with Lactobacillus GG. Gut 2002; 3:405-08.
7. Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 2004; 4:5-10.
8. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999; 5:1107-11.
9. Bai AP, Ouyang Q. Probiotics and inflammatory bowel diseases. Postgrad Med 2006; 968:376-81.
10. Ewaschuk JB, Dieleman LA. Probiotics and prebiotics in chronic inflammatory bowel diseases. World J Gastroenterol 2006; 37:5941-7.
11. Scaldaferri F, Sans M, Vetrano S, Graziani C, De Cristofaro R, Gerlitz B, Repici A, Arena V, Malesci A, Panes J, Grinnell BW, Danese S. Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. J Clin Invest 2007; 7:1951-6.
12. Danese S, Sans M, de la Motte C, Graziani C, West G, Phillips MH, Pola R, Rutella S, Willis J, Gasbarrini A, Fiocchi C. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 2006; 7:2060-7.
13. Rodrigues AC, Cara DC, Fretez SH, Cunha FQ, Vieira EC, Nicoli JR, Vieira LQ. Saccharomyces boulardii stimulates sIgA production and the phagocytic system of gnotobiotic mice. J Appl Microbiol 2000; 3:404-8.
14. Shu Q, Gill HS. A dietary probiotic (Bifidobacterium lactis HN019) reduces the severity of Escherichia coli O157:H7 infection in mice. Med Microbiol. Immunol 2001; 3:147-52.
15. Isolauri E, Sutas Y, Kankaanpaa P, Arvilommi H, Salminen S. Probiotics: effects on immunity. Am J Clin Nutr 2001; 2 (S):444-9.
16. Erickson KL, Hubbard NE. Probiotic immunomodulation in health and disease. J Nutr 2000; 2(S):403-8.
17. Ohashi Y, Hiraguchi M, Ushida K. The composition of intestinal bacteria affects the level of luminal IgA. Biosci Biotechnol Biochem 2006; 12:3031-6.
18. Malin M, Suomalainen H, Saxelin M, Isolauri E. Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab 1996; 3:137-41.
19. Pena JA, Versalovic J. Lactobacillus rhamnosus GG decreases TNF-alpha production in lipopolysaccharide-activated murine macrophages by a contact-independent mechanism. Cell Microbiol 2003; 4:277-82.
20. Lammers KM, Vergopoulos A, Babel N, Gionchetti P, Rizzello F, Morselli C, Caramelli E, Fiorentino M, d'Errico A, Volk HD, Campieri M. Probiotic therapy in the prevention of pouchitis onset: decreased interleukin-1beta, interleukin-8, and interferon-gamma gene expression. Inflamm Bowel Dis 2005; 5:447-51.